Publications by authors named "Nicholas Favatella"

Claim this Profile
M
Mavacamten in symptomatic adolescent patients with obstructive hypertrophic cardiomyopathy: design of the phase 3 SCOUT-HCM trial.
Joseph Rossano, Charles Canter, Cordula Wolf, Nicholas Favatella, Jeffrey Lockman

Am Heart J· February 2026

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
S
Safety and efficacy of apixaban thrombosis prevention in pediatric patients with obesity and acute lymphoblastic leukemia.
Vilmarie Rodriguez, Sarah H O'Brien, Etan Orgel, Corinna L Schultz, Adam J Esbenshade, Nicholas A Favatella

Blood Adv· September 2025

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
C
Clinical Implications of Co-administering Apixaban with Key Interacting Medications.
Nicholas Favatella, David Dalton, Wonkyung Byon, Samira J Merali, Christian Klem

Clin Pharmacol Drug Dev· September 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis
A
Apixaban versus no anticoagulation for the prevention of venous thromboembolism in children with newly diagnosed acute lymphoblastic leukaemia or lymphoma (PREVAPIX-ALL): a phase 3, open-label, randomised, controlled trial.
Sarah H O'Brien, Vilmarie Rodriguez, Glen Lew, Jane W Newburger, Corinna L Schultz, Nicholas A Favatella

Lancet Haematol· January 2024

Social Media Activity not collected for this article yet.

Sign Up to Request Social Media Analysis